Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The decatenation checkpoint.

M Damelin1, T H Bestor

  • 1Department of Genetics and Development, College of Physicians and Surgeons of Columbia University, 701 W. 168th St., New York, NY 10032, USA.

British Journal of Cancer
|January 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gene regulation: stochastic and deterministic effects in gene regulation.

Heredity·2007
Same author

Sex-specific promoters regulate Dnmt3L expression in mouse germ cells.

Human reproduction (Oxford, England)·2006
Same author

Origins of extreme sexual dimorphism in genomic imprinting.

Cytogenetic and genome research·2006
Same author

Transposon silencing and imprint establishment in mammalian germ cells.

Cold Spring Harbor symposia on quantitative biology·2005
Same author

Meiotic defects in a man with non-obstructive azoospermia: case report.

Human reproduction (Oxford, England)·2004
Same author

Dnmt3L and the establishment of maternal genomic imprints.

Science (New York, N.Y.)·2001
Same journal

Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

British journal of cancer·2026
Same journal

Altretamine induces ferroptosis in small cell lung cancer by promoting epigenetic silencing and lysosomal degradation of GPX4.

British journal of cancer·2026
Same journal

Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.

British journal of cancer·2026
Same journal

De novo cancer-related mortality after solid organ transplantation in England: the EpCOT study.

British journal of cancer·2026
Same journal

Planetary Health Diet Index and breast cancer risk.

British journal of cancer·2026
Same journal

Can national lung cancer screening programs be implemented without exacerbating social disparities?

British journal of cancer·2026
See all related articles

The decatenation checkpoint prevents mitotic errors. Its deficiency causes chromosome damage, potentially driving cancer and offering a chemotherapy target.

Area of Science:

  • Cell Biology
  • Genetics
  • Cancer Research

Background:

  • The decatenation checkpoint is crucial for preventing chromosome entanglement before cell division.
  • Deficiencies in this checkpoint can lead to chromosome breakage, nondisjunction, aneuploidy, and rearrangements.
  • Such aberrations are hallmarks of tumor progression and are observed in lung and bladder cancer cell lines.

Purpose of the Study:

  • To investigate the role of the decatenation checkpoint in maintaining genomic stability.
  • To explore the implications of decatenation checkpoint deficiency in cancer stem cells.
  • To identify potential therapeutic targets related to decatenation checkpoint function.

Main Methods:

  • Analysis of decatenation checkpoint function in various cell lines, including cancer and stem cells.

Related Experiment Videos

  • Assessment of chromosome integrity and segregation following checkpoint manipulation.
  • Comparative studies of checkpoint efficiency in normal versus cancerous cells.

    • Main Results:

    • Decatenation checkpoint deficiency leads to significant chromosome breakage and nondisjunction during mitosis.
    • A compromised decatenation checkpoint is prevalent in certain cancer cell lines and stem/progenitor cells.
    • Cancer stem cells may arise from progenitors with ineffective decatenation checkpoints, contributing to tumor heterogeneity.

    Conclusions:

    • An inefficient decatenation checkpoint is a likely source of chromosome aberrations in tumors.
    • Defective decatenation checkpoints in cancer stem cells present a potential vulnerability for targeted chemotherapy.